A recent study from Harvard Medical School, Boston Children's Hospital and OpenAI offers a compelling argument for LLM integration in rare disease diagnosis. With AI-assisted genomic reanalysis, researchers identified 18 new local diagnoses across 376 previously unsolved cases spanning neurodevelopmental and neuromuscular diseases, early psychosis, and sudden unexpected pediatric deaths. The LLM ingested clinical notes, genetic variant data, and standardized symptom terminology, before submitting potential hypotheses which were then adjudicated by clinicians. Across all four cohorts, AI-assisted local diagnoses produced an additional 4.8% diagnostic yield upon reanalysis as compared to original diagnoses; yield rates were highest in the early psychosis cohort (13.3%).
Rare and undiagnosed or misdiagnosed genetic disorders affect millions of global patients, and the clinical community has long recognized the promise of whole-genome sequencing across a range of applications. Clinicians have, for example, identified six emergent arenas for possible whole-genome sequencing usage: pre-conception identifications of Mendelian disorder carriers; prenatal and pre-implantation testing; individual risk for Mendelian disorders; pharmacogenetic testing; direct tissue typing for transplantation; and identification of alleles that increase risk for common disorders.
Before application, however, significant barriers remain: costs are high, clinical validity is uneven, social utility is occasionally dubious, and, as advancements in genomic sequencing supersaturate research pipelines with data, physicians struggle to identify and interpret lesser-known gene variants. Unsurprisingly, then, over half of physicians employ genomic tests that fail to meet accuracy standards, and phenotype-gene associations for rare disorders remain underrepresented in databases like the Online Mendelian Inheritance in Man (OMIM), forcing physicians to manually parse databases like PubMed.
As such, some experts remain cautious. Robert Nussbaum of UCSF suggested that genomic interpretation for identifying risk-associated alleles is still, for now, "more in the realm of entertainment than medicine."
The AI's role was to generate explainable and biologically grounded pathogenic findings by connecting a patient's clinical features with genomic data and existing biomedical evidence. By proposing candidate gene-disease links for clinician review and validation, the model functioned less as a decision-maker and more as a systematic hypothesis engine, capable of rapidly surfacing and prioritizing plausible disease mechanisms from vast genomic datasets.
That the LLM produced new, clinically relevant findings in 18 of 376 rare disease cases suggests that AI-assisted reanalysis may offer a meaningful mechanism for implementing whole-genome sequencing, especially in cases where standard diagnostic methods are exhausted.
Before promising possible gains in, for example, alleles identification or real-world calibration with clinical workflows, larger prospective studies with multicenter evaluation are needed. If validated at scale, however, the hypothesis engine model could provide a durable paradigm for AI integration in medicine and research.